LivingGLP1
Study S002231

Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment Versus Glimepiride Both in Combination With Metformin

Included trial: extracted dataClinicalTrials.gov record

Registration

Registration
NCT01425580
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE2
Masking
NONE
Status
COMPLETED
Enrollment
62
Start
2012-01
Primary completion
2016-08
Lead sponsor
Thomas Nystrom
Conditions
Congestive Heart Failure; Type 2 Diabetes Mellitus
Interventions
DRUG:liraglutide; DRUG:glimepiride; DRUG:Metformin
Results posted
FALSE
Secondary identifiers
EUDRACT_NUMBER:2010-022695-31

Registered primary outcomes

  • Left ventricle longitudinal function and/or functional reserve during rest and/or after exercise using tissue Doppler echocardiography [18 weeks]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0021728Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
Scherbak NN, Diabetes & metabolism journal
2023Randomized trialPMID 37349083DOIcites ClinicalTrials.gov:NCT01425580; registry reference DERIVED:37349083
R0008060Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.
Jendle J, Cardiovascular diabetology
2021Randomized trialPMID 34920733DOIcites ClinicalTrials.gov:NCT01425580; registry reference DERIVED:34920733
R0025252Effects on repetitive 24-hour ambulatory blood pressure in subjects with type II diabetes randomized to liraglutide or glimepiride treatment both in combination with metformin: a randomized open parallel-group study.
Jendle J, Journal of the American Society of Hypertension : JASH
2018Randomized trialPMID 29548934DOIcites ClinicalTrials.gov:NCT01425580; registry reference DERIVED:29548934